
浏览全部资源
扫码关注微信
1. 金昌市人民医院药剂科
2. 芜湖市第二人民医院药剂科
纸质出版日期:2021,
扫 描 看 全 文
杨静, 杨玉琴, 叶军, 等. 益气解毒活络方对早期糖尿病肾病肾小管损伤的影响[J]. 中国医院用药评价与分析, 2021,21(12):1482-1485.
YANG Jing, YANG Yuqin, YE Jun, et al. Effects of Yiqi Jiedu Huoluo Formula on Renal Tubular Injury in Early Diabetic Nephropathy[J]. 2021,21(12):1482-1485.
杨静, 杨玉琴, 叶军, 等. 益气解毒活络方对早期糖尿病肾病肾小管损伤的影响[J]. 中国医院用药评价与分析, 2021,21(12):1482-1485. DOI: 10.14009/j.issn.1672-2124.2021.12.014.
YANG Jing, YANG Yuqin, YE Jun, et al. Effects of Yiqi Jiedu Huoluo Formula on Renal Tubular Injury in Early Diabetic Nephropathy[J]. 2021,21(12):1482-1485. DOI: 10.14009/j.issn.1672-2124.2021.12.014.
目的:探讨益气解毒活络方对早期糖尿病肾病肾小管损伤、外周血单个核细胞磷酸化c-Jun氨基末端激酶(p-JNK)、免疫球蛋白G4(IgG4)和β2微球蛋白(β2-MG)的影响。方法:以2018年10月至2020年1月金昌市人民医院就诊的早期糖尿病肾病患者为研究对象
将106例患者(门诊患者41例
住院患者65例)按照随机数字表法分为观察组和对照组。所有患者均给予生活方式干预等基础治疗
对照组53例患者给予控制血糖、血压和纠正血脂紊乱的对症治疗
观察组53例患者在对照组的基础上给予益气解毒活络方治疗。观察两组患者的临床疗效
治疗前后的空腹血糖(FBG)、糖化血红蛋白(HbA
1
c)和肌酐(CREA)水平
外周血单个核细胞p-JNK水平
IgG4、β2-MG、肾损伤分子1(KIM-1)、中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、24 h尿蛋白定量(24 hPRO)和尿微量白蛋白(m Alb)水平。结果:治疗后
两组患者FBG、HbA
1
c、24 hPRO和mAlb水平均明显低于本组治疗前
且观察组患者明显低于对照组
差异均有统计学意义(P
<
0.05);治疗后
两组患者尿液KIM-1、NGAL、IgG4、β2-MG和外周血单个核细胞p-JNK水平均明显低于本组治疗前
且观察组患者明显低于对照组
差异均有统计学意义(P
<
0.05)。治疗后
两组患者中医证候积分较治疗前明显降低
且观察组患者较对照组明显更低
差异均有统计学意义(P
<
0.05)。观察组患者的总有效率为94.34%(50/53)
明显优于对照组的77.47%(40/53)
差异有统计学意义(P
<
0.05)。结论:益气解毒活络方治疗早期糖尿病肾病
能够显著改善患者的症状
保护肾功能
延缓糖尿病肾病进展
其作用机制可能与干预ROS/JNK信号通路有关。
OBJECTIVE: To probe into the effects of Yiqi Jiedu Huoluo formula on improvement of renal tubule damage
the phosphorylation of c-Jun N-terminal kinase( p-JNK)
immunoglobulin G4( IgG4) and β2 microglobulin( β2-MG) in peripheral bloodmononuclear cells of patients with early diabetic nephropathy. METHODS: Totally 106 patients( 41 outpatients and 65 inpatients) with early diabetic nephropathy admitted into Jinchang People’s Hospital from Oct. 2018 to Jan. 2020 were extracted to be divided into the observation group and the control group. All patients were given basic treatments such as lifestyle intervention
and 53 patients in the control group were given symptomatic treatment to control the blood glucose
blood pressure and correct dyslipidemia
while 53 patients in the observation group received Yiqi Jiedu Huoluo formula on the basis of the control group. Clinical efficacy
fasting blood glucose( FBG)
glycosylated hemoglobin( HbA
1
c) and creatinine( CREA) levels
peripheral blood mononuclear cell P-JNK
IgG4
β2-Mg
kidney injury molecule1( KIM-1)
neutrophil gelatinase-associated lipid carrier protein( NGAL)
24 h urinary protein quantization( 24 hPRO) and urinary microalbumin( m Alb) levels before and after treatment in two groups were observed. RESULTS: After treatment
the levels of FBG
HbA
1
c
24 hPRO and m Alb of two groups were significantly lower than those before treatment
and the observation group was significantly lower than the control group
with statistically significant differences( P
<
0. 05). After treatment
the urine KIM-1
NGAL
IgG4
β2-MG and peripheral blood mononuclear cells p-JNK of two groups were significantly lower than those before treatment
and the observation group was significantly lower than the control group
with statistically significant differences( P
<
0. 05). After treatment
the scores of traditional Chinese medicine syndrome in both groups were significantly lower than those before treatment
and the observation group was significantly lower than the control group
with statistically significant differences( P
<
0. 05). The total effective rate of the observation group was 94. 34%( 50/53)
significantly better than 77. 47%( 40/53) of the control group
the difference was statistically significant( P
<
0. 05).CONCLUSIONS: Yiqi Jiedu Huoluo formula in the treatment of early diabetic nephropathy can significantly improve the symptoms of patients
protect the kidney function and delay the progression of diabetic nephropathy. Its mechanism of action may be related to the intervention of ROS/JNK signaling pathway.
益气解毒活络方糖尿病肾病肾小管损伤磷酸化c-Jun氨基末端激酶
Yiqi Jiedu Huoluo formulaDiabetic nephropathyRenal tubular damagePhosphorylated c-Jun N-terminal kinase
0
浏览量
31
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621